Arcutis Biotherapeutics Financials - Benzinga

Arcutis Biotherapeutics Inc

ARQTNASDAQ

Trade with Public

Trade with Public

$23.97

At close: Sep 1, 5:00 PM EST

$23.94

-0.03-0.13%

After Hours: 7:55 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Arcutis Biotherapeutics Financials

Arcutis Biotherapeutics (ARQT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Arcutis Biotherapeutics Q2 EPS $0.11 Beats $0.03 Estimate, Sales $129.861M Beat $118.852M Estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.03 by 266.67 percent. This is a 184.62 percent increase over losses of $(0.13) per

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Arcutis Biotherapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $105.398M Beat $101.261M Estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.06) by 50 percent. This is a 55 percent increase over losses of $(0.20) per share

Benzinga Newsdesk

PRO
Arcutis Biotherapeutics Q4 EPS $0.13 Beats $0.10 Estimate, Sales $129.503M Beat $113.055M Estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.10 by 32.65 percent. This is a 244.44 percent increase over losses of $(0.09) per share

Benzinga Newsdesk

Earnings Scheduled For February 25, 2026

Benzinga Insights

Preview: Arcutis Biotherapeutics's Earnings

Benzinga Insights